Adimab LLC. Announces 50th Therapeutic Program Under Its Funded Discovery Partnerships
LEBANON, N.H.--(BUSINESS WIRE)--Adimab LLC, a leader in the discovery and optimization of monoclonal and bispecific antibodies, today announced the 50th therapeutic program under its funded discovery partnerships. Adimab launched its antibody discovery and optimization platform in the middle of 2009 and in less than five years has formed collaborations with more than 20 partners encompassing 50 therapeutic programs. In addition, Adimab announced today that new commercial licenses have been exercised from the funded discovery partnerships with Arsanis Biosciences, Merrimack Pharmaceuticals and Mersana Therapeutics.
Help employers find you! Check out all the jobs and post your resume.